【国金证券:首予先健科技(01302.HK)“增持”评级 目标价1.8港元】国金证券发布研究报告称,首次覆盖先健科技(01302.HK),给予“增持”评级,看好公司在心脑血管介入领域的长期发展,预计公司2024-2026年营业收入12.56/16.87/20.76亿元,同比-1%/+34%/+23%;归母净利润2.94/3.73/4.66亿元,同比+12%/+27%/+25%。目标价1.8港元/股。

金融界
03 Jan
国金证券发布研究报告称,首次覆盖先健科技(01302.HK),给予“增持”评级,看好公司在心脑血管介入领域的长期发展,预计公司2024-2026年营业收入12.56/16.87/20.76亿元,同比-1%/+34%/+23%;归母净利润2.94/3.73/4.66亿元,同比+12%/+27%/+25%。目标价1.8港元/股。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10